Document is current
Any future updates will be listed below
-
Authors
Gholami, Fatemeh
Hamidi Farahani, Ramin
Karimi Rahjerdi, Ahmad
Ahi, Mohammadreza
Sheidaei, Ali
Gohari, Kimiya
Rahimi, Zahra
Ansarifar, Akram
Basiri, Pouria
Moradi, Milad
Jahangiri, Arash
Naderi, Kosar
Ghasemi, Soheil
Khatami, Pezhman
Honari, Mohsen
Khodaverdloo, Samane
Shooshtari, Mohammad
Mehr Azin, Hajar
Moradi, Sohrab
Shafaghi, Batool
Allahyari, Hossein
Monazah, Arina
Khodaei Poor, Ali
Taghva, Zahra
Bakhshande, Hooman
Karimi Nia, Mohammad
Solaymani Dodaran, Masoud
Forooghizade, Mohsen
-
Clinical Trials BETA
Clinical trials referenced in this document:
irct20210206050259n2 at Iranian Registry of Clinical TrialsDocuments that mention this clinical trial
Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18–70 years
https://doi.org/10.1186/s12879-023-08079-1
- License Information
-
More Information
Article History
Received: 24 July 2022
Accepted: 13 February 2023
First Online: 24 February 2023
Declarations
:
: The trial was conducted in accordance with the 1964 Helsinki Declaration and its later amendments. The clinical trial protocol was approved by the Iranian National Ethics Committee for research (approval number IR. NREC.1400.003, 7th June 2021). Informed consent was obtained from all participants.
: Not applicable.
: SGH, PKH, MH, SKH, MSH, HM, SM, BSH, HA, AM, and AKH are employees of Milad Daro Noor Pharmaceutical (MDNP). MSD is an Iran University of Medical Science (IUMS) employee. MSD, AA, MA, ASH, ZR, FGH, and KG are members of the clinical trial center of the Iran University of Medical Science that acted as academic CRO. All other authors declare no other competing interests.
